19745-07-4

Basic information

• Product Name: 2,5-Dichloropyrazine
• Synonyms: 2,5-DICHLOROPYRAZINE;NSC 349788;2,5-Dichloro-1,4-diazine
• CAS NO: 19745-07-4
• Molecular Formula: C₄H₂Cl₂N₂
• Molecular Weight: 148.98
• Product Categories: Piperazine series;Pyrazines;Pyrazine;Building Blocks
• Mol File: 19745-07-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 0 °C (approx)
• Boiling Point: 184.4 °C at 760 mmHg
• Flash Point: 81.5 °C
• Appearance: colourless liquid
• Density: 1.493 g/cm³
• Vapor Pressure: 1mmHg at 25°C
• Refractive Index: 1.559
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -4.23±0.10(Predicted)
• CAS DataBase Reference: 2,5-Dichloropyrazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-Dichloropyrazine(19745-07-4)
• EPA Substance Registry System: 2,5-Dichloropyrazine(19745-07-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• Hazardous Substances Data: 19745-07-4(Hazardous Substances Data)

Usage

Chemical Properties

Colorless liquid

InChI:InChI=1/C4H2Cl2N2/c5-3-1-7-4(6)2-8-3/h1-2H

Upstream product

• 374063-92-0 2-hydroxy-5-bromopyrazine 
• 6863-76-9 3-chloropyrazine 1-oxide 
• 33332-29-5 2-amino-5-chloropyrazine 
• 290-37-9 1,4-pyrazine 
• 7732-18-5 water 
• 7782-50-5 chlorine 
• 14508-49-7 2-chloropyrazin 
• 89180-45-0 5-chloro-1,2-dihydro-2-oxopyrazine 
• 89180-45-0 5-chloropyrazine-2-ol 

Downstream Products

• 426829-52-9 tert-Butyl 4-(6-Chloro-2-Pyrazinyl)-1-Piperazinecarboxylate 
• 299441-13-7 (5-chloropyrazin-2-yl)hydrazine 
• 1245215-80-8 N-(5-chloropyrazin-2-yl)-N-methyl ethanesulfonamide 
• 1023813-21-9 3,6-dichloropyrazine-2-carboxamide 
• 1017781-68-8 4-(5-chloropyrazin-2-yl)morpholine 

Relevant articles and documents

Favipiravir intermediate and synthesis method of favipiravir

The invention discloses a favipiravir intermediate and a synthesis method of favipiravir. The synthesis method comprises the following steps: taking 2,5-dihalopyrazine as an initial raw material, reacting 2,5-dihalopyrazine with formamide under the action of an oxide and a catalyst to generate 6-halo-3-chloro-2-amide pyrazine; carrying out a reaction on 6-halo-3-chloro-2-amide pyrazine under the action of a dehydration chlorinating agent and an acid-binding agent to generate a favipiravir intermediate 3,6-dichloro-3-cyanopyrazine; carrying out an aromatic ring fluorination reaction on the obtained favipiravir intermediate and potassium fluoride in dimethyl sulfoxide to generate 3,6-difluoro-3-cyanopyrazine; adding the 3,6-difluoro-3-cyanopyrazine into a water solution containing sodium acetate, and carrying out hydrolysis to obtain 6-fluoro-3-hydroxyl-2-cyanopyrazine; and finally, carrying out a cyano hydrolysis reaction to obtain favipiravir. A mixture of 2,5-dichloropyrazine and 2-chloro-5-bromopyrazine are used as raw materials to synthesize the favipiravir intermediate, the raw material cost is remarkably reduced, and the provided synthesis method has the technical advantages of high yield and low cost.

AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacycloalkane derivatives of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, such as atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.

AMIDOPYRAZOLE DERIVATIVE

A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.